Overview

Dedicated Drug-Drug Interaction (DDI) Study in Healthy Volunteers

Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
A Phase 1, Open-Label, Non-Randomized, Fixed Sequence Study to Evaluate the Steady-state Pharmacokinetics of BLD-0409, Nintedanib and Pirfenidone when Administered Concurrently in Healthy Volunteers
Phase:
Phase 1
Details
Lead Sponsor:
Blade Therapeutics
Treatments:
Nintedanib
Pirfenidone